{"slideshow_credits": null, "snippet": "Two members of the Senate Finance Committee asked Gilead Sciences to defend the more than $80,000 cost of Sovaldi, citing the expense to federal health care programs.", "abstract": "Sen Ron Wyden, chairman of the Senate Finance Committee, along with one another member, ask Gilead Sciences to defend high cost of its breakthrough treatment for hepatitis; cite massive expanse that $80,000 drug C Sovaldi will represent for federal health care programs.", "section_name": "U.S.", "print_page": "2", "document_type": "article", "byline": {"person": [], "organization": "REUTERS", "original": "By REUTERS", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/07/12/us/senators-query-hepatitis-c-drugs-high-costs.html", "lead_paragraph": "Two members of the Senate Finance Committee asked Gilead Sciences to defend the more than $80,000 cost of Sovaldi, citing the expense to federal health care programs.", "headline": {"main": "Senators Query Hepatitis C Drug\u2019s High Costs", "print_headline": "Senators Query Hepatitis C Drug\u2019s High Costs", "content_kicker": "Business Briefing"}, "_id": "53c0845a38f0d871b1c32225", "word_count": "166", "multimedia": [], "pub_date": "2014-07-12T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Gilead Sciences Inc", "name": "organizations", "is_major": "Y", "rank": "4"}, {"value": "Hepatitis", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Health Insurance and Managed Care", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "7"}, {"value": "Sovaldi (Drug)", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Wyden, Ron", "name": "persons", "is_major": "Y", "rank": "6"}, {"value": "Senate Committee on Finance", "name": "organizations", "is_major": "N", "rank": "3"}], "blog": [], "subsection_name": null, "type_of_material": "Brief"}